Retrieve available abstracts of 11 articles: HTML format
Single Articles
April 2025
ALMEIDA BA, Paixao ES, Pitta ML, Barreto ML, et al Missed opportunities for equity: a crucial perspective on the Lancet's Zika virus
research Series.
Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00226. PubMed
February 2025
LACKRITZ EM, Ng LC, Marques ETA, Rabe IB, et al Zika virus: advancing a priority research agenda for preparedness and response.
Lancet Infect Dis. 2025 Feb 27:S1473-3099(24)00794. PubMedAbstract available
OSTROWSKY JT, Katzelnick LC, Bourne N, Barrett ADT, et al Zika virus vaccines and monoclonal antibodies: a priority agenda for research and
development.
Lancet Infect Dis. 2025 Feb 27:S1473-3099(24)00750. PubMedAbstract available
ABAD-FRANCH F, Carvajal-Cortes JJ, Rabelo ACL, Gusmao EVV, et al Mosquito-disseminated pyriproxyfen for mosquito-borne disease control in Belo
Horizonte, Brazil: a pragmatic, before-after control-intervention paired-series
trial.
Lancet Infect Dis. 2025;25:176-187. PubMedAbstract available
January 2025
KIRBY T Ana Bispo-from polio to Zika virus and beyond.
Lancet Infect Dis. 2025;25:21. PubMed
September 2024
BRICKLEY EB, Miranda-Filho DB, Ximenes RAA Preparing for the rapid research response to the possible vertical transmission
of Oropouche virus: lessons from a decade of congenital Zika research.
Lancet Infect Dis. 2024 Sep 27:S1473-3099(24)00618. PubMed
January 2024
SALJE H Achieving zero deaths from dengue virus under evolving population immunity.
Lancet Infect Dis. 2024;24:12-13. PubMed
June 2023
LOW JG, Ooi EE Inactivated Zika virus vaccine and the complexity of flavivirus antigenicity.
Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00202. PubMed
KOREN MA, Lin L, Eckels KH, De La Barrera R, et al Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate
in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine
in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical
trial.
Lancet Infect Dis. 2023 Jun 27:S1473-3099(23)00192. PubMedAbstract available
January 2023
WILDER-SMITH A, Durbin A Promising efforts to develop an mRNA vaccine against Zika.
Lancet Infect Dis. 2023 Jan 19:S1473-3099(22)00827. PubMed
ESSINK B, Chu L, Seger W, Barranco E, et al The safety and immunogenicity of two Zika virus mRNA vaccine candidates in
healthy flavivirus baseline seropositive and seronegative adults: the results of
two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Lancet Infect Dis. 2023 Jan 19:S1473-3099(22)00764. PubMedAbstract available